Development of 3D-QSAR models for 5-Lipoxygenase antagonists: chalcones

5-Lipoxygenase inhibitors are of current interest for asthma therapy and inflammatory diseases. In order to identify the essential structural and physicochemical requirements in terms of common biophoric sites (pharmacophore) and secondary sites for binding and interacting with 5-lipoxygenase, a ser...

Full description

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry Vol. 10; no. 12; pp. 4035 - 4041
Main Authors Arockia Babu, M, Shakya, Neeraj, Prathipati, Philip, Kaskhedikar, S.G, Saxena, Anil K
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 01.12.2002
Elsevier Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:5-Lipoxygenase inhibitors are of current interest for asthma therapy and inflammatory diseases. In order to identify the essential structural and physicochemical requirements in terms of common biophoric sites (pharmacophore) and secondary sites for binding and interacting with 5-lipoxygenase, a series of 51 compounds of chalcones has been used for the development of 3D-QSAR models on APEX-3D expert system. Among several models, the two models have been identified with the statistical criteria R 2>0.75, Chance <0.001 and Match >0.7. Both the models (nos 1 and 2) with three biophoric sites and four secondary sites, showed very good correlation ( r>0.9) between the observed and calculated or predicted activities. The 3D-QSAR models, quantifying the essential structural and physicochemical requirements in terms of common biophoric sites (pharmacophore) and secondary sites for binding and interacting with 5-lipoxygenase, have been developed for a series of chalcones using APEX-3D expert system.
ISSN:0968-0896
1464-3391
DOI:10.1016/S0968-0896(02)00313-9